Copyright © 2004 by the European Society of Cardiology.
Review
Drug-eluting stents: an early systematic review to inform policy
a Liverpool Reviews and Implementation Group, The Sherrington Buildings, Ashton Street, Liverpool L69 3GE, UK
b Cardiology Department, Barnet General Hospital, Wellhouse Lane, Barnet EN5 3DJ, UK
* Corresponding author. Tel.: +44-151-794-5541; fax: +44-151-794-5477
E-mail address: rahill{at}liv.ac.uk
Received 15 December 2003; revised 9 March 2004; accepted 18 March 2004 See page 895 for the editorial comment on this review2.
Abstract
Aims To provide systematic assessment of the clinical effectiveness of drug-eluting stents (DES) versus non-DES to inform national guidance.
Methods and results The review was conducted according to internationally recognised methods. The search strategy identified published (7) and unpublished (7) randomised controlled trials comparing the use of DES to non-DES. Outcomes included death, acute myocardial infarction (AMI), revascularisation, event rate (composite of adverse events), and binary restenosis. Data synthesis included descriptive statistics and meta-analysis. Fourteen randomised clinical trials comparing DES to non-DES and involving 5747 patients were identified.
There were reductions in event rates between DES and non-DES; odds ratio (OR) 0.63 (95% confidence interval [95% CI] 0.47, 0.84, 
) for paclitaxel-eluting stents at 12 months, OR 0.30 (95% CI 0.22, 0.42, 
) for sirolimus-eluting stents at 12 months. Combined event rates were inconsistently defined across trials and were primarily composed of revascularisations, possibly driven by protocol-required angiograms. DES reduced binary restenosis rates at angiogram compared to non-DES. No significant differences in rates of death or AMI were identified.
Conclusion The early data available indicate that DES reduce adverse cardiac events, mainly revascularisations. However, these data are limited in terms of patient numbers, length of follow-up, and method of outcome assessment. The evaluation of rapidly evolving technologies requires the inclusion of data not routinely considered for inclusion in systematic reviews of effectiveness.
Key Words: Drug-eluting stents • Stents • Interventional cardiology • Systematic review • Health technology assessment • Policy
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Drug-eluting stents: the new gold standard for percutaneous coronary revascularisation
- Antonio Colombo and Ioannis Iakovou
EHJ 2004 25: 895-897.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  L. T. Newsome, M. A. Kutcher, and R. L. Royster Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention Anesth. Analg., August 1, 2008; 107(2): 552 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L. Pinto Slottow and R. Waksman Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel Meeting on the Endeavor Zotarolimus-Eluting Coronary Stent Circulation, March 25, 2008; 117(12): 1603 - 1608. [Full Text] [PDF]
|
|
|
|
|
|
P. Ortolani, M. Balducelli, P. Marzaroli, G. Piovaccari, A. Menozzi, V. Guiducci, P. Sangiorgio, F. Tarantino, G. Geraci, F. Castriota, et al. Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions: Results From a Real-World Multicenter Registry Circulation, February 19, 2008; 117(7): 923 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Zeymer and R. Zahn Drug-eluting stents: effective and safe for every patient and every lesion? Eur. Heart J., November 1, 2007; 28(21): 2559 - 2560. [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Kereiakes Does Clopidogrel Each Day Keep Stent Thrombosis Away? JAMA, January 10, 2007; 297(2): 209 - 211. [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Taggart Coronary Artery Bypass Grafting is Still the Best Treatment for Multivessel and Left Main Disease, But Patients Need to Know Ann. Thorac. Surg., December 1, 2006; 82(6): 1966 - 1975. [Full Text] [PDF]
|
|
|
|
|
|
A. J. Nordmann, M. Briel, and H. C. Bucher Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis Eur. Heart J., December 1, 2006; 27(23): 2784 - 2814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Smith, R. M. Califf, R. H. Tuttle, L. K. Shaw, K. L. Lee, E. R. Delong, R. E. Lilly, M. H. Sketch Jr, E. D. Peterson, and R. H. Jones Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. Ann. Thorac. Surg., October 1, 2006; 82(4): 1420 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Breeman, M. E. Bertrand, J. P. Ottervanger, S. Hoeks, M. Lenzen, U. Sechtem, V. Legrand, M.-J. de Boer, W. Wijns, E. Boersma, et al. Diabetes does not influence treatment decisions regarding revascularization in patients with stable coronary artery disease. Diabetes Care, September 1, 2006; 29(9): 2003 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Blindt, F. Vogt, I. Astafieva, C. Fach, M. Hristov, N. Krott, B. Seitz, A. Kapurniotu, C. Kwok, M. Dewor, et al. A Novel Drug-Eluting Stent Coated With an Integrin-Binding Cyclic Arg-Gly-Asp Peptide Inhibits Neointimal Hyperplasia by Recruiting Endothelial Progenitor Cells J. Am. Coll. Cardiol., May 2, 2006; 47(9): 1786 - 1795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Stettler, S Allemann, M Egger, S Windecker, B Meier, and P Diem Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials Heart, May 1, 2006; 92(5): 650 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Raja Drug-Eluting Stents and the Future of Coronary Artery Bypass Surgery: Facts and Fiction. Ann. Thorac. Surg., March 1, 2006; 81(3): 1162 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G.L. Biondi-Zoccai, P. Agostoni, G. M. Sangiorgi, F. Airoldi, J. Cosgrave, A. Chieffo, R. Barbagallo, C. Tamburino, G. Vittori, E. Falchetti, et al. Incidence, predictors, and outcomes of coronary dissections left untreated after drug-eluting stent implantation Eur. Heart J., March 1, 2006; 27(5): 540 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. G L Biondi-Zoccai, M. Lotrionte, A. Abbate, L. Testa, E. Remigi, F. Burzotta, M. Valgimigli, E. Romagnoli, F. Crea, and P. Agostoni Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study BMJ, January 28, 2006; 332(7535): 202 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U Dietz, N Holz, C Dauer, and H Lambertz Shortening the stent length reduces restenosis with bare metal stents: matched pair comparison of short stenting and conventional stenting Heart, January 1, 2006; 92(1): 80 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Bagust, A D Grayson, N D Palmer, R A Perry, and T Walley Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study Heart, January 1, 2006; 92(1): 68 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M Franks and S. F Gardner AGI-1067: A Novel Vascular Protectant for Prevention of Restenosis Ann. Pharmacother., January 1, 2006; 40(1): 66 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Califf Stenting or Surgery: An Opportunity to Do it Right J. Am. Coll. Cardiol., August 16, 2005; 46(4): 589 - 591. [Full Text] [PDF]
|
|
|
|
|
|
A. A. Bavry, D. J. Kumbhani, T. J. Helton, and D. L. Bhatt What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: A meta-analysis J. Am. Coll. Cardiol., March 15, 2005; 45(6): 941 - 946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Scheen, F. Warzee, and V. M.G. Legrand Drug-eluting stents: meta-analysis in diabetic patients Eur. Heart J., December 1, 2004; 25(23): 2167 - 2168. [Full Text] [PDF]
|
|
|
|
|
|
A. Bagust, A. Bakhai, R. Dickson, Y. Dundar, R. A Hill, and T. Walley Exploring groups at high risk of restenosis Eur. Heart J., December 1, 2004; 25(23): 2168 - 2169. [Full Text] [PDF]
|
|
|
|
|
|
Minerva BMJ, September 11, 2004; 329(7466): E323 - E323. [Full Text] [PDF]
|
|
|
|
|
|
P. Eriksson Long-term clopidogrel therapy in the drug eluting stent era: beyond CREDO and CURE-PCI: Reply Eur. Heart J., August 1, 2004; 25(15): 1364 - 1365. [Full Text] [PDF]
|
|
|
|
|
|
Minerva BMJ, July 10, 2004; 329(7457): 120 - 120. [Full Text] [PDF]
|
|